Results 211 to 220 of about 1,661 (294)

Obstructive Salivary Gland Disorders - A Malaysian Patient Series. [PDF]

open access: yesInt Arch Otorhinolaryngol
Subha ST, Osman M, Narayanan P.
europepmc   +1 more source

Metabolic Reprogramming and GM‐CSF Secretion in Areca Nut‐Activated Fibroblasts Drive Oral Precancer Progression

open access: yesOral Diseases, EarlyView.
ABSTRACT Objective Oral cancer, with a rising global incidence and poor prognosis, is associated with areca nut use in South and Southeast Asia. In this study, we addressed the effects of areca nut extract (ANE) on oral carcinogenesis by modulating fibroblast behavior in oral tissue.
Yen‐Yun Wang   +9 more
wiley   +1 more source

Laser Acupuncture on the Management of Xerostomia in Sjögren's Disease: A Randomized Clinical Trial

open access: yesOral Diseases, EarlyView.
ABSTRACT Objectives This study evaluated the efficacy of photobiomodulation (PBM) at acupuncture points for managing xerostomia in patients with Sjögren's Disease. Material and Methods In this randomized, double‐blind clinical trial, 50 patients were assigned to PBM group (n = 22) or sham‐PBM group (n = 28).
Matheus Ferreira Linares   +5 more
wiley   +1 more source

Giant submandibular sialolith conservatively treated

open access: yesAutopsy and Case Reports, 2017
Gustavo Henrique Campos Rodrigues   +3 more
doaj  

Clinicopathological and Prognostic Features of Pleomorphic Adenoma, Recurrent Pleomorphic Adenoma, and Carcinoma ex Pleomorphic Adenoma: A 20‐Year Retrospective Analysis

open access: yesOral Diseases, EarlyView.
ABSTRACT Background Pleomorphic adenoma (PA) is the most common salivary gland tumor, and a subset may recur as recurrent PA (RPA) or progress to carcinoma ex pleomorphic adenoma (CXPA). However, comparative evaluations of their biological behavior and prognostic factors remain limited.
Talita de Carvalho Kimura   +7 more
wiley   +1 more source

Sialolipoma of the Parotid Gland: A Systematic Review. [PDF]

open access: yesCureus
Tsaprazlis T   +4 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy